Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 3/20 | 0.36 |
| ▸ | MAX | P61244 | 3/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | BLVRB | P30043 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343678 | 0.93 | MAPT (0.35) | MYCMAXGCKMAPTGAA | |
| SCHEMBL1342804 | 0.92 | GCK (0.38) | MYCMAXGCKEP300PTPN1 | |
| SCHEMBL1343330 | 0.90 | TSHR (0.35) | MYCMAXGCKMAPTGAA | |
| SCHEMBL1342464 | 0.89 | MYC (0.33) | MYCMAXGCK | |
| SCHEMBL1341841 | 0.86 | MYC (0.40) | MYCMAXEP300MAPTGAA | |
| SCHEMBL1342262 | 0.85 | GCK (0.40) | MYCMAXGCKMAPTGAA | |
| SCHEMBL1341247 | 0.85 | GCK (0.38) | MYCMAXGCKMAPTGAA | |
| SCHEMBL1342463 | 0.83 | MYC (0.33) | MYCMAXGCK | |
| SCHEMBL1342834 | 0.83 | TSHR (0.38) | MAPTGAALMNATP53MEN1 | |
| SCHEMBL1343044 | 0.82 | MYC (0.37) | MYCMAXGCKEP300GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MYC 180/4885MAX 2951/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.